UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03 avr. 2024 07h00 HE
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
27 juin 2023 07h15 HE
|
Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
30 mars 2021 07h57 HE
|
Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
16 oct. 2020 07h00 HE
|
Arch Biopartners
TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial...
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
28 juil. 2020 08h13 HE
|
Arch Biopartners
TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL
17 mars 2020 11h21 HE
|
Arch Biopartners
TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final...
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
18 déc. 2019 09h27 HE
|
Arch Biopartners
TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury
04 déc. 2019 08h46 HE
|
Arch Biopartners
TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)
07 nov. 2019 07h00 HE
|
Arch Biopartners
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
22 août 2019 12h24 HE
|
Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....